This study sought to (1) identify patterns of hypnotic use among persons aged 50 and older for 8 years and (2) describe characteristics and correlates associated with them. Methods: A representative sample of national health insurance system beneficiaries was followed up from 2006 through 2013; individuals were grouped according to hypnotic delivery trajectories by latent class mixed models. Results: We identified four different temporal trajectories of hypnotic delivery among users. Delivery was occasional for 40% and regular for 60% (quasicontinuous "use": 27%; increasingly frequent over time: 17%; decreasingly frequent: 16%). Quasi-continuous "users" received hypnotics for more than 70% of the follow-up period and occasional "users" for less than 8%. We found no clear evidence of dose escalation. The three regular-delivery trajectories shared similar correlates (psychiatric disorders, somatic comorbidity, and coprescriptions of antidepressants or antipsychotics), but association with somatic comorbidity was highest by far for quasi-continuous "users." Conclusions: Our results suggest that chronic hypnotic use covers different patterns resulting from different long-term temporal delivery trajectories. Because difficulties in stopping or reducing use may vary greatly according to these trajectories, patients may need individualized management approaches.
INTRODUCTION
Hypnotics (hypnotic benzodiazepines (BZD) and "z-drugs") are among the most prescribed medications in the world. [1] [2] [3] Although their efficacy in treating sleep disorders has been demonstrated, 4, 5 these medications present serious side effects: increased risks of traffic accidents 6, 7 and falls, 6, 8 psychomotor impairment, and cognitive decline, particularly among older individuals. 9, 10 These side effects are thought to be particularly detrimental for older people: 7, 11 an estimated 30% of people older than 65 years will fall at least once annually. 12 A meta-analysis has shown that sedative hypnotic use is associated with falls (odds ratio (OR)=1.6; 95% CI 1.4-1.7) and with psychomotor side effects (dizziness, loss of balance: OR 2.3; p = .07). 13 The prevalence of cognitive impairment without dementia varies from 10% at 65-74 years to 30% after 84 years, 14 and the meta-analysis mentioned above showed a strong association between sedative hypnotic use and cognitive effects (OR 4.8, p < .01). 13 These results and those about the benefits of hypnotics in older people have led some authors to consider that "over 60, the benefits of these drugs may not justify the increased risks, particularly if the patient has additional risk factors for cognitive or psychomotor adverse events." 13 In 1983, a National Institute of Health Consensus Conference Statement 15 recommended only short-term and intermittent use of hypnotics to treat chronic insomnia because of the risks associated with these drugs, especially but not only in older people. This approach, however, was not based on empirical data. 16 A 2005 State of the Science Conference Statement recognized that in many cases short-term pharmacologic treatment with short-acting hypnotic drugs is inadequate to treat chronic insomnia. 16 Randomized, controlled studies of benzodiazepine receptor agonists such as zolpidem have demonstrated continued efficacy without significant complications for 6 months and even longer. 17 Although FDA class labeling for hypnotics before 2005 implicitly recommended short treatment durations, they stopped addressing treatment duration that year. The Clinical Guideline for the Evaluation and Chronic Management of Chronic Insomnia in Adults 17 states that an initial pharmacotherapy treatment period of 2-4 weeks may be appropriate for many patients, but that a subset of patients with severe chronic insomnia may be appropriate candidates for longerterm of chronic maintenance treatment. Some authors nonetheless stress that the benefits and risks of hypnotic use should be carefully weighed in older people. 13 Recommendations that the duration of hypnotic treatment in people older than 65 not exceeding 4 weeks were issued in 2007 by the French Haute Autorité de Santé (the National Authority for Health 18 ) and in 2004 by NICE in the United Kingdom; 19 both recommendations remain in effect.
Strong evidence shows that long-term hypnotic use continues to be common among the general population, especially the elderly, in many countries. 20 Reasons for chronic use are
Statement of Significance
This article reports that chronic hypnotic use covers different delivery patterns formed by different long-term temporal trajectories. Dose escalation was not found in any of these trajectories, but difficulties in stopping or reducing hypnotic consumption may differ according to pattern and require individualized management. Results also suggest that limiting hypnotic use to occasional discontinuous use, compatible with some guidelines including those in France, is possible for a considerable fraction of users; they thus offer a positive perspective to both clinicians and patients. Further research is also needed to determine whether risk levels vary according to pattern of hypnotic use.
complex: they may include the prescriber's knowledge and attitudes toward hypnotics and patients, perceived or real difficulties in accessing alternative treatments, as well as patients' fears of symptom return, disagreement with the necessity to stop those drugs, and in some cases, the experience of withdrawal symptoms. [21] [22] [23] [24] Comparing the prevalence of long-term hypnotic use between studies is difficult; however, definitions of long-term use (from one month to several years), follow-up duration (from one year to 10 or more), and population sampling schemes vary greatly between studies, as underscored in a systematic review of 41 studies. 20 The prevalence of long-term use (all definitions) among adult users of anxiolytics/hypnotics in these studies ranges from 6% to 76%, and heterogeneity in prevalence rates remained substantial even when analysis was limited to studies with a common definition of long-term use. Overall, evidence of an association between long-term use and older age is strong. 2, 20, [25] [26] [27] A study estimated the prevalence of current use of anxiolytics/hypnotics among the general adult population in France at 7.5% in 2001, reporting that 76% of users used these drugs for 6 months or longer. 25 Since 2010, use of anxiolytics and hypnotics has risen in France. 18 Some studies suggest that patterns of use for drugs such as zolpidem and zopiclone can differ; 27, 28 they can include, for example, non-problematic users who comply with guidelines, users with mental disorders who do not comply with guidelines, and problematic users (duration or daily doses far beyond recommendations). Few studies, however, have explored the temporal patterns of hypnotic prescriptions over long periods (>1 year) and their correlates, although such information could prove useful for adapting and targeting intervention strategies against misuse. [29] [30] [31] This article reports the results of a retrospective cohort study based on reimbursement data from the French National Health Insurance Fund (NHIF) that sought to: (1) identify the various temporal patterns (trajectories) of hypnotic use frequency (using delivery as a proxy for use) among persons aged 50 and older, over a long period of time, and determine their prevalence; and (2) describe treatment characteristics (duration, dose levels, and potential escalation) and correlates (demographic, psychotropic drug co-prescriptions, psychiatric and somatic comorbidity, and mortality) associated with these patterns.
METHODS

Study Population
We used the "Echantillon Généraliste des Bénéficiaires" database (permanent sample of beneficiaries-EGB), a permanent, representative, and anonymized sample of persons affiliated with the three major national health insurance funds in France. 32 These funds cover more than 90% of the French general population and include salaried workers, agricultural workers and farmers, and self-employed workers as well as their dependents. Since data for the two latter categories were only included in the EGB in 2011, we limited this study to salaried workers (85% of the French general population 32 ). The EGB was created in 2005, by a national random sampling of 1/97th of the French population, stratified for age and gender; it records information on their health care consumption and includes data on reimbursement claims for drugs purchased in the community, classified with the Anatomical Therapeutic Chemical (ATC) index.
This study selected all individuals aged 50 years or more in the EGB on January 1, 2006, and followed them up until the end of 2013. Those who died or withdrew from the insurance fund covered by EGB during the follow-up period were censored at the date of the event.
Outcome: Hypnotic Delivery Over the Follow-up Period No pharmacy based initiatives have been taken in France to oversee GPs' hypnotic prescriptions to people in the community. Using the ATC index, we collected information on hypnotic drugs (see supplementary file S1 for the list of selected ATC codes) dispensed during the follow-up period. For this study, we selected only benzodiazepine hypnotics marketed in France throughout the study period for the treatment of sleep problems. Therefore, flurazepam, quazepam, zalelplon, and brotizolam were not included (because not authorized in France), nor was clonazepam, which is restricted to the treatment of epilepsy here. Because we focused on hypnotic drugs, antidepressants and anxiolytics (including alprazolam) were not considered in this study. The follow-up period was discretized into 3-month periods. For each of these 32 periods (temporal statistical units in our analyses), we built a binary variable of "at least one hypnotic delivery." Although the dispensing of a drug does not guarantee that it will be used, hypnotic delivery trajectories were considered proxies for hypnotic use trajectories. Hypnotic delivery trajectories were estimated according to the presence/absence of a delivery in each of these statistical units (see the Statistical Analysis). The trajectories identified were then characterized according to the number and duration of hypnotic treatment episodes during the follow-up period as well as the daily-defined doses. We used a published method 33 to estimate the duration of a hypnotic treatment episode from information about drug delivery dates. Because French pharmacies are not allowed to deliver more than 28 days' worth of a drug treatment, this method postulates that the duration of hypnotic treatment corresponding to one hypnotic delivery is 28 days, regardless of the number of boxes of medicine delivered. A treatment episode was considered discontinued if no renewal occurred within 56 days after the last delivery (i.e., the 28-day period with delivery plus the following 28-day period without a delivery). We adapted the definition proposed by Kurko et al. for chronic use (at least six months a year) and defined individual chronic hypnotic use in our study as use for 50% or more of the follow-up period. 20 Using information from the English National Health Service's National Institute for Health and Care Excellence 34 and the South Australia Health Department 35 on diazepam milligram equivalents for hypnotics, we also translated the overall dose of prescribed hypnotics into diazepam equivalent amounts. We calculated daily diazepam equivalent doses (DDED, mg/day) by dividing the total dose over the follow-up period by the cumulative number of treatment days.
Other Psychotropic Drugs Dispensed
As we did for hypnotic drugs, we collected information on other psychotropic drugs dispensed during the follow-up period:
antidepressants (ATC: N06A), anxiolytics (ATC: N05BA), and antipsychotics (ATC: N05A except lithium). Binary variables were built for each drug class: at least one delivery over the follow-up period. The number of visits with general practitioners (GPs) and with specialists during the follow-up period was also available for all members of the cohort.
Somatic Multimorbidity Score
We calculated a somatic multimorbidity pharmacy-based score and used Huber's classification of medications 36 and the ATC index to assign dispensed drugs to 18 chronic somatic conditions. 37 A chronic condition was defined as present in a year when a person received at least one drug belonging to one of the 18 ATC groups generated by Huber's classification during one year. The weighting scheme for calculating the individual chronic condition (ICC) score is described in supplementary file S2. Each patient's ICC score was then calculated for each year of follow-up as the weighted sum of the chronic conditions identified by this procedure. 38 We used data related to the long-term illness (LTI) status available in the French social insurance system to identify persons with long-term psychiatric disorders, Parkinson's or Alzheimer's diseases, or related dementias. LTI status is granted to beneficiaries with long-term and costly diseases and exempts them from copayments for any medical care associated with that disease, regardless of their income level. 39 LTIs currently cover 30 groups of diseases.
Statistical Analysis
We used latent class mixed models 40 (LCMMs) to identify subgroups of individuals with similar trajectories of hypnotic delivery during the follow-up period. Trajectory analysis uses a semiparametric, group-based modeling strategy to identify homogeneous latent classes based on longitudinal data. 41 Although interpreted in the same way as latent class analyses (LCA), LCMMs differ by enabling consideration of within-class variation. 42 Accordingly, LCMM can classify subjects with slightly different patterns (trajectories) more easily into the same class than LCA can. 42 We will call these classes "trajectories" hereafter.
The Bayesian information criterion (BIC) determined the optimal number of trajectories for the LCMM. 43 Starting with a two-trajectory solution, we added a trajectory at a time, testing each model fit (i.e., a better fit corresponded to a lower BIC) and balancing it with our objective of identifying distinctive and interpretable trajectories. 44 In latent class models, individual class-membership probabilities (posterior probabilities) can be calculated by using the Bayes theorem as the probability of belonging to a latent class given the information collected, to evaluate the model's goodness of fit. 40 We also compared the observed and predicted trajectories to assess the quality of the classification.
Missing data during the follow-up period for censored individuals were handled by LCMM under the missing-at-random assumption, 40 which allows individuals with missing values to be assigned to their most likely trajectory. 40 To control for the non-random distribution of the probability of death during follow-up (higher among older individuals, men, and people with comorbidities), we stratified the analysis according to age at inclusion (50-64, 65-74, 75-84 , and >84) and gender and implemented an LCMM in each resulting stratum. We also ran these models with and without adjustment for the somatic comorbidity score over the follow-up period and for LTI status for a psychiatric condition at inclusion.
It was not always possible to run an LCMM in each stratum, because they did not always converge on solutions. To allow the estimation of parameters in a reasonable time (<24 hours), we performed LCMMs with 3-month periods as statistical units (to reduce the number of individual observations) and on smaller randomly selected samples of 10 000 persons in each stratum. For the strata with fewer than 10 000 persons in the EGB (persons aged 85 years or older), LCMMs were performed on the entire stratum.
To analyze the correlates of the trajectories, we further excluded subjects classified in the so-called "non-user trajectory," where the probability of hypnotic delivery over the entire follow-up period was close to zero; this further reduced the sample size. We also excluded subjects censored during the first two years of follow-up, because at least two years were needed to evaluate modifications in the comorbidity score. The correlates of each hypnotic delivery trajectory were studied with multivariate polynomial logistic regression.
Following different authors in various health fields, we used the Behavioural Model of Health Care Use 45 as a broad framework to describe the correlates of the trajectories. [46] [47] [48] This model distinguishes between predisposing, need, and enabling (organizational) factors. The following covariates could be included: (1) predisposing factors: age class (50-64, 65-74, 75-84, >84); sex; (2) needs: LTIs for psychiatric disorders, Parkinson's or Alzheimer's disease or related dementia at inclusion or during follow-up; somatic comorbidity score during the first year after inclusion and its course over follow-up; and delivery of anxiolytics, antidepressants, and antipsychotics during follow-up. Organizational factors were beyond the scope of this article. Apart from these variables, we also adjusted the analyses for average annual number of visits with GPs or specialists during the follow-up period. We categorized continuous variables according to quartiles (<Q1, Q1-Q3, >Q3) and used the Zhang correction to estimate risk ratios from odds ratios. 49 Given that the prevalence of each trajectory may be relatively high, this method makes it possible to derive estimates that better represents the true relative risk. 49 Since the NHIF does not include prescriptions dispensed by public or private hospital pharmacies during hospital stays, we performed a sensitivity analysis to test whether potential missing data for hypnotics dispensed at hospital could have biased the results; the value of the outcome was considered missing when a person had at least one hospital stay longer than 15 days during a given 3-month period.
LCMMs were analyzed with R software 50 and the LCMM package. 40 Other statistical analyses were performed with SAS statistical software, version 9.4 (SAS Institute, Inc., Cary, NC, USA).
RESULTS
Of the 164 265 persons included in the cohort on January 1, 2006, 45.0% were men, 53.8% were aged 50-64, and 2.7% had an LTI for a psychiatric condition at that time. During the 8-year follow-up period, 15.9% of the individuals died (Table 1) , and 32.6% made at least one hypnotic purchase. GPs prescribed 93% of the hypnotics.
The solution that offered the best compromise between parsimony, fit, and interpretability included five patterns of hypnotic delivery trajectories ( Figure 1 , Table 2 ). Over all strata, the mean posterior class-membership probability was estimated at 0.94 (±0.10), which indicated that classification quality was good. Adjustment for somatic and psychiatric comorbidity had a limited impact on the shape of most trajectories, except among people aged 85+, who included a lower proportion of nonusers after this adjustment (results available upon request).
Trajectory 1 included individuals with a permanent very low or null probability of hypnotic delivery during the follow-up ("non-users"); they accounted for 72.4% to 82.4% of the cohort, depending on stratum. Overall, the probability of at least one hypnotic delivery over the entire 8-year follow-up period was estimated at 10.6% in this trajectory, and the probability of at least two hypnotic deliveries in two different 3-month periods was only 1.6%.
Trajectory 2 included individuals whose probability of hypnotic delivery was greater than 80% throughout the entire follow-up period ("quasi-continuous users"). Their cumulative duration of hypnotic treatment exceeded 69% of the follow-up period, and the average DDED over this period ranged from 5.0 to 6.2 mg/day, depending on stratum. The pattern was slightly different for those aged 85 years or older at the study start date; it showed a trend in which the probability of hypnotic delivery (Figure 1 ) and the DDED both decreased after three years of follow-up. The prevalence of trajectory 2 varied from 2.9% to 9.7%, was higher among women than men, and increased with age (Table 2) .
Trajectory 3 included users whose probability of hypnotic delivery tended to increase over the follow-up period ("increasingly frequent users"). Its prevalence varied between 2.5% and 4.7% according to stratum, was higher among women than men (p < .001), relatively stable with age in men, and highest from ages 65 through 84 years in women. The cumulative duration of hypnotic treatments ranged from 25% to 42% of the follow-up period depending on stratum, and the average DDED remained relatively stable, around 5 mg/day over the follow-up period (Table 2 ). In particular, our results for the "increasing use" trajectory suggest that, except for the increase in the frequency of delivery (and prescriptions), the distribution of specific drugs and the doses prescribed remained similar (Table 2 , Supplementary file S3).
Trajectory 4 mirrored the preceding one: it included users with a trend toward decreasing probability of hypnotic delivery ("decreasingly frequent use") but a relatively stable DDED. Its prevalence varied between 2.0% and 4.9% according to stratum, was higher among women than men (p < .001), and increased with age in both sexes. Trajectory 5 included users with a persistent low probability (between 10% and 20%) of hypnotic purchase over the entire follow-up period ("occasional users"). In women aged 85+, the pattern differed: the probability of hypnotic purchase showed an increasing trend. The prevalence of trajectory 5 varied from 4.4% to 11.4% according to stratum and was similar among men and women, except in the 85+ age group. The total duration of hypnotic treatments accounted for 6% to 9% of the follow-up period for most strata, except among women 85+ (16%). The DDED was relatively stable at around 4.5 mg.
The prevalence of chronic delivery was highest in trajectory 2, second highest in trajectory 3, lower in trajectory 4, and lowest in trajectory 5 ( Table 2) . On average over all strata, "quasi-continuous users" received hypnotics for 72% of the follow-up period, "increasingly frequent users" for 31%, "decreasingly frequent users" for 33%, and "occasional users" for 7%.
Treating hypnotic delivery as missing when a patient had been hospitalized for longer than 15 days had no impact on the shapes or prevalences of hypnotic delivery trajectories (results available upon request).
For the multivariable analysis (excluding the class of "non-users"), we merged trajectories 3 and 5 in the stratum of "women 85+" because of the increase in the probability of hypnotic delivery in trajectory 5 ( Figure 1) . Compared with "occasional use," the probability of regular (quasi-continuous or increasingly or decreasingly frequent) delivery of hypnotics increased with age, among women, and for those with psychiatric disorders, and somatic comorbidity at inclusion (except for "increasingly frequent users" for comorbidity) ( Table 3) . "Decreasingly frequent use" was positively associated with a low frequency of comorbidity during follow-up and with Parkinson's disease or dementia at inclusion (these neurologic diseases were not associated with quasi-continuous and increasingly frequent "use"). "Regular use" of hypnotics was also positively associated with co-prescriptions of antidepressants and/or antipsychotics. The probability of "quasi-continuous use" and "increasingly frequent use" increased among those with a high number of GP visits. The probability of "quasi-continuous use" and "decreasingly frequent use" decreased among those with a high number of visits to specialists, regardless of their specialization.
DISCUSSION
Using LCMMs, we identified four different temporal trajectories of hypnotic delivery (in addition to the "non-user" trajectory of 72 to 82% of the population) over eight years. Overall, hypnotic delivery was occasional for 40% of users and regular for 60% (quasi-continuous: 27% of all users; increasing over time: 17%; decreasing: 16%). On average, "quasi-continuous users" received hypnotics for more than 70% of the follow-up period, and "occasional users" for less than 8%. No clear dose escalation was observed in any of the trajectories. The three "regular-use" trajectories shared similar correlates (psychiatric disorders, Parkinson's disease or dementia, somatic comorbidity, and coprescriptions of antidepressants and antipsychotics). Nonetheless, the association with somatic comorbidity was strongest by far among "quasi-continuous users." . The shape of most trajectories, except for latent class 5 among women aged 85+, remained relatively stable among all age and sex strata. For all age and sex strata, the prevalence of the latent classes is reported in Table 2 . Number of incident hypnotic treatment episodes Our typology of hypnotic delivery is an important new finding, providing evidence of different long-term trends over time in hypnotic use. The finding that "occasional use" was the most prevalent trajectory among users is encouraging. The finding that most of the treatment episodes in this class were short (Table 2) suggests that hypnotic use was most often discontinuous, did not involve dose escalation, and complied with French guidelines. 18 The identification of a "decreasingly frequent use" trajectory is also a positive finding, as it suggests that a significant percentage of "regular users" were progressively reducing their frequency of hypnotic use. There was also evidence in some strata that DDEDs were diminishing ( Table 2 ). The fact that this trajectory was observed in the oldest groups is especially encouraging (Figure 1 ). This deceleration was, however, spread over a very long period, perhaps because sleep difficulties might still supervene despite progressive withdrawal over months or even years 51, 52 or because people might find it difficult, for various reasons mentioned in the Introduction, to stop the treatment. 21 Guidelines recommend that hypnotic use should be stopped very progressively and that several months may be necessary to do so. Our results, which reflect patients' real lives, suggest that far longer delays may sometimes be necessary to achieve this objective. 53 The prevalence of "increasingly frequent use" was slightly higher than that of "decreasing use." This result, together with the stable "quasi-continuous use" between 2006 and 2013, is in line with the upturn in hypnotic use noted in France since 2010. 54, 55 Moreover, the substantial percentage of treatment episodes exceeding the recommended duration among all trajectories is consistent with the finding of at most partial adherence to the guidelines published in France over the period 2006-2013. 56 Our results about "quasi-continuous" and "increasingly frequent uses" are worrisome, at least for older people in these trajectories, because they are known to be at an increased risk of various serious side effects, including falls and cognitive impairment. The benefits of regular hypnotic use in these people might be outweighed by these risks, as several meta-analyses have argued. 12, 13, 57 We did not find clear evidence of dose escalation, however, and average DDEDs remained low over the 8-year follow-up with only slight differences between the four delivery patterns. Studies show that the most common pattern of long-term BZD delivery in the general population in France and elsewhere involves a low, stable dosage, either occasionally or daily, for years. 55, 58, 59 The lack of dose escalation in our study might be explained by the use of the hypnotics that are the most frequently prescribed (from 60% to 70% depending on stratum): Z-drugs (zopiclone and zolpidem). They have short half-lives and no evidence of potential for abuse or dependence according to initial clinical trials, 60 even though WHO has placed zolpidem, but not zopiclone, on its list of Schedule IV drugs. 27 Our results for "increasingly frequent users" (Table 2) suggest that people may start using their treatment discontinuously and then progressively take it ever more continuously. People in this class should be considered priority targets, both to improve our understanding of the reasons for this increase and to maintain, to the extent possible, their initial discontinuous use, especially among older people. Among the study population (n = 164 265), we randomly selected samples of 10 000 persons in each age and sex stratum to reduce calculation time of the LCMM (except for persons >84 years old at inclusion, n = 7641 for women, n = 3109 for men). Latent classes of hypnotic users were derived from trajectory analysis of hypnotic delivery. a (Total duration of hypnotic treatment episode(s) during follow-up/duration of follow-up)*100. Hypnotic treatment episodes were calculated using discrete 28-day periods after the first hypnotic delivery. Treatment episodes were considered discontinued if no renewal occurred within 56 days of the date of first delivery. Duration of treatment episode = date of last delivery + 28 days − date of 1st delivery.
b
Value during the first two years of follow-up/average over entire follow-up period/value during the last two years of follow-up. Persons with no hypnotic delivery during the considered period are excluded. Numerous studies have shown that BZD use is associated with chronic somatic comorbidity. 20, 38 The finding that this association was strongest among quasi-permanent hypnotic users suggests that severe chronic conditions might be an obstacle to stopping hypnotic use, although this result cannot be interpreted in terms of causality. Chronic pain, various physical symptoms, stress, and even depression can cause sleep problems. 61 Of particular concern is the fact that people with chronic comorbidities receive multiple drugs that may increase the risks of some side effects of BZDs (e.g., falls and confusion), again especially among older people.
While psychiatric comorbidity (as well as antidepressant use) was associated with continuous, increasing, and decreasing use of hypnotics, neurologic diseases (Parkinson, dementia) were associated only with decreasing use of hypnotics over time. Degenerative neurologic disorders that do or may lead to dementia, such as Alzheimer's and Parkinson's, exacerbate age-related changes in sleep. 62 This decreasing use among these patients is noteworthy; the 8-year span of our study is long enough to reflect some disease progression among these conditions in a sample of this size. Some guidelines recommend that non-pharmacological approaches should be considered first in patients with Alzheimer's disease. If hypnotics are used, the lowest effective dose of the selected agent should be used for the shortest time possible. 63 GPs prescribe most hypnotics and should consider suggesting non-pharmacological approaches, such as cognitive behavioural therapy (CBT) for insomnia, as suggested in some guidelines. 18, 64 It has been shown to produce better results than zopiclone in the short-and long-term treatment of insomnia in the elderly, 65 although we note that others report that CBT might be less effective in the elderly or associated with lower compliance than pharmacotherapy. 59, 66 Limitations Some limitations of this study must be considered in interpreting its results. The delivery of hypnotics does not guarantee that they will be used. This potential bias might have resulted in overestimation of hypnotic use prevalence in this study, but should be less marked for regular or chronic use, as regularly repeated purchase of drugs suggests that at least some portion of them are indeed used. Because the NHIF databases do a Among persons for whom hypnotic delivery trajectories were estimated (n = 70 750), persons with a zero (or close to zero) probability of hypnotic delivery during the entire follow-up period (see Table 2 and Figure 1) were excluded (77.7%) as well as those who were censored during the first year of follow-up (2.4%). Latent classes of hypnotic users were derived from trajectory analysis of hypnotic delivery. b First (Q1) and third (Q3) quartiles of the data set (see Table 1 ).
not routinely record information about illness severity or reasons for prescription, the strength of the associations between hypnotic use and psychiatric disorders or somatic comorbidity might be underestimated. Nonetheless, pharmacy-based comorbidity scores have been shown to capture somatic comorbidity well. 36, 37, 67 The lack of information about insomnia diagnosis/symptoms and patterns of use of non-pharmacological insomnia treatment in the NHIF database is another limitation. Moreover, neither social (including income) and cognitive factors and beliefs about insomnia and its treatment nor perceived health care requirements (need factors) could be included in the multivariable analysis because this information is not recorded in the NHIF database. Similarly, adherence to prescribed instructions is unavailable. All of this information would be useful for a better understanding of the temporal patterns of hypnotic use, but it would require a different design. Notwithstanding these limitations, the very large sample and long follow-up period allowed us to study trajectory of use with good accuracy and statistical power and to identify longterm trends.
Moreover, the choice of LCMM to study trajectory patterns allowed us to take within-class variation into account and makes the analysis robust to selective death and dropping out under the quite reasonable hypothesis that death and dropout risks do not depend on unobserved current hypnotic consumption after adjustment for explanatory variables and past observed hypnotic consumption. 68 Stratifying the LCCMs for age and sex and adjusting for somatic and psychiatric comorbidity should have limited the bias incurred by death because these variables, taken together, are strongly predictive of death. 67 Understanding why recommendations regarding the duration of hypnotic treatment are often not followed despite repeated warnings about the risks associated with chronic BZD use, especially in older people, should be a research priority. Apart from the characteristics of hypnotic drugs themselves, patients face barriers to adherence. In particular, sleeping problems and demand for hypnotics increase with age. 69 But research efforts should also focus on GPs, who are responsible for most hypnotic prescriptions, especially in France, to improve our understanding of their perceptions of the problem. Research should also focus on proposing and evaluating strategies to deal with the dilemmas they face when trying to reduce hypnotic use among patients dependent on sleeping pills 53, 54 or to help them find alternatives to avoid prescribing hypnotic treatments or to limit the duration of these treatments from the start.
